Craig Taylor
Angestellt, Chief Executive Officer, Silamed, Inc.
Scottsdale, Vereinigte Staaten
Werdegang
Berufserfahrung von Craig Taylor
Bis heute 17 Jahre und 6 Monate, seit 2007
Chief Executive Officer
Silamed, Inc.
Joined Silamed in 2007. Silamed is an early-stage pharmaceutical company that uses silicon substitution chemistry to rapidly and inexpensively develop improved and proprietary derivatives of existing drugs. Silamed’s initial development efforts are focused in the treatment of cancer.
6 Jahre und 2 Monate, Nov. 2000 - Dez. 2006
Partner
Adams Street Partners, LLC
sponsored 15 private company investments, including: CombinatoRx (CRXX), GlobeImmune, Intarcia, Jazz Pharma (JAZZ), Light Sciences Oncology, Mpex, Myogen (acquired by Gilead), and Oncomed. Board member Light Sciences Oncology, Revascular Therapeutics, CardioVention; board observer NxStage (NXTM).
4 Jahre, Sep. 1996 - Aug. 2000
Associate Director
G.D. Searle / Pharmacia (Now Pfizer)
Oncology Business Development Cardiovascular Marketing
2 Jahre und 1 Monat, Sep. 1994 - Sep. 1996
Associate Consultant
Integral, Inc. (Analysis Group)
Operations and product development strategy and performance improvement
3 Jahre, Okt. 1990 - Sep. 1993
Project Manager / Senior Research Biochemist
Abbott Laboratories
Diagnostics Product Development, AxSym
Ausbildung von Craig Taylor
2 Jahre, Sep. 1992 - Aug. 1994
Finance and Marketing
University of Chicago GSB
4 Jahre und 3 Monate, Aug. 1986 - Okt. 1990
Biochemistry and Molecular Biology
Georgetown University
3 Jahre und 10 Monate, Aug. 1981 - Mai 1985
Biology and Economics
Grinnell College
Sprachen
Englisch
-